What’s Propelling RXi Pharmaceuticals Corp (RXI) to Increase? The Stock Formed a Bullish Double Top Pattern

August 9, 2017 - By Henry Gaston

The chart of RXi Pharmaceuticals Corp (RXI) shows a double top with $0.67 target or 7.00 % above today’s $0.63 share price. The 5 months chart pattern indicates low risk for the $13.89 million company. It was reported on Aug, 9 by Finviz.com. If the $0.67 price target is reached, the company will be worth $972,300 more. Double tops are rare but powerful chart patterns.

About 111,938 shares traded. RXi Pharmaceuticals Corp (NASDAQ:RXII) has declined 75.22% since August 9, 2016 and is downtrending. It has underperformed by 91.92% the S&P500.

More notable recent RXi Pharmaceuticals Corp (NASDAQ:RXII) news were published by: Prnewswire.com which released: “RXi Pharmaceuticals to Present at Leading Investor and Healthcare Conferences” on February 08, 2017, also Prnewswire.com with their article: “RXi Pharmaceuticals Granted 180-Day Extension by Nasdaq Stock Market to Regain …” published on August 03, 2017, Prnewswire.com published: “RXi Pharmaceuticals Completes Acquisition of MirImmune Inc. and Appoints New …” on January 09, 2017. More interesting news about RXi Pharmaceuticals Corp (NASDAQ:RXII) were released by: Seekingalpha.com and their article: “Rxi Pharmaceuticals: One Undervalued Biotech That Keeps Building Its Pipeline …” published on May 01, 2015 as well as Prnewswire.com‘s news article titled: “RXi Pharmaceuticals Announces Closing of $11.5 Million Underwritten Public …” with publication date: December 21, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.